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ABSTRACT
Critically ill patients are at increased risk of fractures during rehabilitation, and can experience impaired healing of traumatic and surgical
bone fractures. In addition, markers of bone resorption are markedly increased in critically ill patients, while markers of bone formation
are decreased. In the current study, we have directly investigated the effect of critical illness on bone metabolism and repair. In a human
in vitro model of critical illness, Fluorescence-activated cell sorting (FACS) analysis revealed an increase in circulating CD14þ/CD11bþ
osteoclast precursors in critically ill patient peripheral blood compared to healthy controls. In addition, the formation of osteoclasts was
increased in patient peripheral bloodmononuclear cell (PBMC) cultures compared to healthy controls, both in the presence and absence
of osteoclastogenic factors receptor activator of NF-kB ligand (RANKL) and macrophage colony-stimulating factor (M-CSF). Culturing
PBMCs with 10% critically ill patient serum further increased osteoclast formation and activity in patient PBMCs only, and neutralization
studies revealed that immunoglobulin G (IgG) antibody signaling through the immunoreceptor Fc receptor common g chain III (FcRgIII)
played an important role. When analyzing bone formation, no differences in osteogenic differentiation were observed using human
periosteal-derived cells (hPDCs) treated with patient serum in vitro, but a decrease in the expression of vascular endothelial growth factor
receptor 1 (VEGF-R1) suggested impaired vascularization. This was confirmed using serum-treated hPDCs implanted onto calcium
phosphate scaffolds in a murine in vivo model of bone formation, where decreased vascularization and increased osteoclast activity led
to a decrease in bone formation in scaffolds with patient serum-treated hPDCs. Together, these findings may help to define novel
therapeutic targets to prevent bone loss and optimize fracture healing in critically ill patients.  2012 American Society for Bone and
Mineral Research.
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Introduction
Critical illness, whether evoked by sepsis, trauma, or extensivesurgery, predisposes patients to prolonged dependency
on vital organ support. We have previously reported that markers
of lean tissue wasting such as skeletal muscle and bone evoke
the catabolic state of prolonged critical illness.(1) Specifically,
circulating biomarkers of bone resorption are substantially
elevated whereas markers of bone formation are low.(2) Such an
imbalance may predispose critically ill patients to impaired
fracture healing, osteoporosis, and increased risk of new
fractures during intensive care unit (ICU) stay or rehabilitation.
A recent retrospective case-cohort study revealed a significant
increase in fracture risk in survivors of critical illness,(3) implying a
clinically relevant impact of the reported alterations in bone
biomarkers. Until now, however, no studies have directly
addressed the effect of critical illness on bone metabolism
and repair at the tissue and cellular level.
Normal bone turnover depends on a tight coupling between
the function of mature osteoclasts, osteoblasts, and vasculariza-
tion. This coupling requires a complex equilibrium of mechanical,
endocrine, and nutritional factors. Prolonged critically ill patients
are immobilized and suffer from a wide variety of endocrine
and inflammatory disturbances, including hypercortisolism,
hyposomatotropism, secondary hypothyroidism, hypogonad-
ism, vitamin D deficiency, and elevated inflammatory cytokine
levels.(2) Each of these factors, separately or in combination, may
contribute to increased bone resorption and decreased bone
formation.
In other disease states characterized by excessive bone loss,
such as postmenopausal osteoporosis, cystic fibrosis, and Paget’s
disease, increased osteoclast formation and activity from
peripheral blood mononuclear cells (PBMCs) has been
reported,(4) both in the presence and absence of the canonical
osteoclast activation factors, receptor activator of NF-kB ligand
(RANKL) and macrophage colony stimulating factor (M-CSF).(5)
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Increased osteoclast formation in such disorders appears to be
related to elevated serum tumor necrosis factor a (TNF-a),
interleukin 1 (IL-1), and IL-6 levels(6); however, recently,
immunomodulatory factors such as Fc receptor common g
chain III (FcRgIII) have also been shown to influence osteoclas-
togenesis.(7) To date, the behavior of PBMCs derived from
critically ill patients has not been investigated.
New bone formation and fracture healing requires precursor
cells located in the periosteum, a specialized connective tissue
forming a thin fibrous membrane firmly anchored to bone.
Human periosteal-derived cells (hPDCs) have previously been
used as a clinically relevant model to examine bone formation
and fracture healing.(8)
Here, we performed a series of studies to address the impact of
prolonged critical illness on bone catabolism and repair at the
cellular level. In an in vitro model, we investigated whether
PBMCs isolated from critically ill patients are predisposed to
differentiate into osteoclasts, and the effect of humoral and
immunomodulatory factors present in patient serum on
osteoclast formation and activity. In addition, we assessed
how these humoral factors of critical illness influenced osteoblast
differentiation of human periosteal cells in vitro and bone
formation in vivo in a murine model.
Patients and Methods
In vitro model of bone resorption during critical illness
Experimental subjects
We collected human peripheral blood from prolonged critically
ill patients (n¼ 12, 26–80 years of age, mean age 57 16.39
years) and healthy control volunteers, matched for age, sex, and
body mass index (BMI) (n¼ 12, 23–81 years of age, mean age
57 17.44 years) (Table 1). Serum samples were also collected
from these individuals, and filtered through a 0.2-mmmembrane
(Millipore, Overijse, Belgium). The baseline characteristics of
critically ill patients are described in Table 1. All protocols were
approved by the Institutional Review Board of Leuven University.
Written informed consent was obtained from all healthy
volunteers and from the patients or, when the patient was
unable to give consent, from the closest family member. Prior to
sample collection, it was ensured that no steroidal drugs or
bisphosphonates had been taken by patients or healthy
volunteers in the past 12 months.
Flow cytometry
We carried out fluorescence-activated cell sorting (FACS) analysis
on freshly isolated peripheral blood samples from a separate
population of age-, sex-, and BMI-matched critically ill patients
and healthy controls (n¼ 5 per group). Osteoclast precursors
were detected by staining fresh blood samples with allophy-
cocyanin (APC)-conjugated anti-VNR (R&D Systems, Abindgdon,
UK), phycoerythrin (PE)-conjugated anti-CD14, and fluorescein
isothiocyanate (FITC)-conjugated anti-CD11b (both from BD
Biosciences, Erembodegem, Belgium), or with the corresponding
isotype control at 48C for 30 minutes. Following incubation with
the required antibody combinations, red blood cells were lysed
(RBC lysis buffer; eBioscience, Vienna, Austria), and the remaining
cells washed in FACS buffer before being incubated with 7-AAD
viability dye for 15 minutes. FACS analysis was then carried out
immediately. We treated double-positive CD14þ/CD11bþ cells as
early osteoclast precursors, and triple-positive CD14þ/CD11bþ/
VNRþ cells as osteoclast precursors, according to the litera-
ture.(9,10) Flow cytometry was performed on a FACSCalibur flow
cytometer (BD Biosciences). The expression of membrane
antigens was analyzed using BD FACSDiva software (BD
Biosciences).
PBMC isolation and culture
We isolated PBMCs from 20mL whole blood of patients or
healthy volunteers by means of Ficoll-Paque Plus (GE Healthcare,
Brussels, Belgium) density gradient centrifugation according to
the manufacturer’s instructions. Cells were stored in liquid
nitrogen until use and seeded at a density of 5 105 cells per
well.(11) All cultures were performed in quadruplicate in 16-well
culture slides (VWR, Leuven, Belgium) or 16-well BD Biocoat
Osteologic Slides (BD Biosciences), and cells were cultured in a
modified essential medium (a-MEM) supplemented with 10%
fetal bovine serum (FBS), 100 IU/mL penicillin, and 100mg/mL
streptomycin (‘‘complete medium’’), or complete medium plus
M-CSF (25 ng/mL; R&D Systems) and RANKL (30 ng/mL; Cell
Sciences, Canton, MA, USA). In order to study the effect of
circulating factors on osteoclast formation, PBMCs were also
Table 1. Characteristics of Critically Ill Patients and Age-, Sex-,
and BMI-Matched Healthy Volunteer Controls Whose Peripheral
Blood Was Used to Isolate PBMCs for In Vitro Osteoclast
Differentiation Studies
Characteristic Patients Controls p
n 12 12
Age (years), median (IQR) 57 (26–80) 57 (23–81) >0.99
Male gender, % 71.4 71.4 >0.99
BMI (kg/m2), mean SD 24.5 3.8 25.9 3.5 0.37
ICU stay upon day of
sampling (days),
median (IQR)
13 (7–134) NA
APACHE-II score on
admission,
median (IQR)
28 (16–40) NA
Admission diagnosis, n NA
Complicated
cardiac/vascular
surgery
3
Abdominal sepsis 3
Burn injury 1
Complicated
neurosurgery
3
Trauma 1
Complicated
laryngectomy
1
APACHE II¼Acute Physiology and Chronic Health Evaluation II; BMI¼ -
body mass index; ICU¼ intensive care unit; IQR¼ interquartile range;
PBMC¼peripheral blood mononuclear cell.
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grown in complete medium containing 10% human healthy
volunteer serum (HS) or 10% patient serum (PS). For cytokine
and immunoreceptor neutralization experiments, PBMCs were
grown in complete medium/10% PS for 14 days, in the presence
of anti-TNF-a/anti-IL-6 (1mg/mL and 8mg/mL, respectively; R&D
Systems), anti-FcgRIII (20mg/mL), or a combination of anti-TNF-
a/anti-IL-6 and anti-FcgRIII antibodies. All cultures were main-
tained at 378C in a humidified atmosphere with 5% CO2.
Osteoclast formation and activity
After 14 days, we fixed and stained PBMCs for the osteoclast-
specific marker tartrate-resistant acid phosphate (TRAP), and the
nuclear marker 4,6-diamidino-2-phenylindole (DAPI), as previ-
ously described.(4) The formation of TRAP positive multinucleat-
ed (more than three nuclei) cells was quantified by counting the
multinuclear stained cells in each well.(4) Filamentous (F)-actin
rings representing active osteoclasts were visualized after
staining of the actin cytoskeleton with the toxin phalloidin
conjugated to FITC (Sigma–Aldrich, Bornem, Belgium), and
quantified by counting. To evaluate osteoclast activity, cells were
removed from the hydroxyapatite-coated wells with 14% sodium
hypochlorite, and the mineral layer was stained with Von-Kossa
as previously described.(12) Lacunar resorption was determined
by measuring the total area unstained by Von-Kossa (total area
resorbed) using ImageJ software (National Institutes of Health,
Bethesda, MD, USA), and was expressed as the total percentage
of the surface reabsorbed.
In-vitro model of osteoblast differentiation during critical
illness
Cell culture
We obtained hPDCs from the Laboratory for Skeletal Develop-
ment and Joint Disorders, Katholieke Universiteit Leuven,
Leuven, Belgium, and maintained them as previously de-
scribed.(13) All experiments were carried out with expanded cell
populations between passage five and seven, with a seeding
density of 4500 cells/cm2. After 48 hours in culture, the growth
medium of in vitro osteogenic assays was replaced using
osteogenic medium, which consisted of FBS-free growth
medium supplemented with 100 nM dexamethasone (Sigma-
Aldrich), 10mM glycerol-2-phosphate disodium salt hydrate
(Sigma-Aldrich), 50mM L-ascorbic acid 2-phosphate sesquimag-
nesium salt hydrate (Sigma-Aldrich), and 10% serum (10% FBS,
10% PS, or 10% HS). The medium was replaced every 3 days.
In vitro mineralization assay
We analyzed hPDCs for in vitro mineralization using Alizarin red
to detect mineral deposits, as previously described.(14) Quantifi-
cation of calcium mineral deposits was performed by dissolving
the dye with 10% cetylpyridinium chloride (in demineralized
water) for 10min at room temperature (RT). Absorbance was
measured spectrophotometrically at 570 nm.
Gene expression analysis
We seeded hPDCs at 4500 cells/cm2 and treated them for 7 days
with osteogenic medium and FBS, HS, or PS. Total RNA was
isolated using the RNeasy kit (Qiagen Benelux, Venlo,
Netherlands) and cDNA was synthesized with the SuperScript
III First Strand synthesis system for real-time PCR (Invitrogen).
Quantitative real-time SYBR Green (Invitrogen) PCR was
performed according to the manufacturer’s protocol, with
mRNA levels normalized to b-actin expression. SYBR Green
qPCR primers were designed to span an intron so that only RNA-
specific amplification was possible (runt-related transcription
factor 2 [RUNX2]-F, 50-CGCATTCCTCATCCCAGTAT-30; RUNX2-R,
50-GCCTGGGGTCTGTAATCTGA-30; collagen, type I, alpha 1 [COL1A1]-
F, 50-GACGAAGACATCCCACCAAT-30; COL1A1-R, 50-AGATCACGT-
CATCGCACAAC-30; alkaline phosphatase [ALP]-F, 50-GGACATG-
CAGTACGTAGCTGA-30; ALP-R, 50-GTCAATTCTGCCTCCTTCCA-30;
vascular endothelial growth factor A [VEGFA]-F, 50-CCCACTGAG-
GAGTCCAACAT-30; VEGFA-R, 50-GCATTCACATTTGTTGTGCTG-30;
vascular endothelial growth factor receptor 1 [VEGF-R1]-F, 50-
AAGCAAACCACACTGGCTTC-30; and VEGF-R1-R, 50-CGGGGATTT-
CACTGTACATCT-30). Total RNA samples subjected to cDNA
synthesis reactions in the absence of reverse transcriptase
were included as negative controls and relative differences in
expression were calculated using the 2DCT method.(15)
Western immunoblotting
For protein expression analysis, we seeded hPDCs at 4500 cells/cm2
and treated them for 7 days with osteogenic medium and FBS,
HS, or PS. To detect VEGFR1, Rabbit anti-human VEGFR1
primary antibody (Abcam, Cambridge, UK; 1:500) was incubated
overnight at 48C. Binding of goat anti-rabbit immunoglobulin
G (IgG) horseradish peroxidase (HRP) secondary antibody
(DakoCytomation, Glostrup, Denmark; 1:2000) was visualized
by enhanced chemiluminescence (ECL). Normalization for total
protein was performed by re-probing themembrane withmouse
anti-mouse beta-actin (Abcam; 1:1000) for 1 hour at RT, followed
by goat anti-mouse IgG HRP (DakoCytomation; 1:2000) for 1 hour
at RT.
In vivo model of bone formation during critical illness
In vivo bone formation
We analyzed in vivo bone formation as described.(8) Briefly,
hPDCs (passage five) were seeded at 4500 cells/cm2 and treated
for 7 days with DMEM and 10% FBS, HS, or PS. After 7 days, the
cells were trypsin-released, centrifuged, and resuspended at a
concentration of 50 million cells/mL. Subsequently, 20mL of the
cell suspension was applied to the upper surface of each 21-mm3
calcium phosphate (CaP) NuOss scaffold. To allow cell attach-
ment, the seeded scaffolds were incubated overnight at 378C.
After incubation, the constructs were directly implanted
subcutaneously in the back at the cervical region of NMRI-nu/nu
mice. The implants were collected after 56 days of implantation.
Each explant was fixed in 4% formaldehyde, scanned by micro–
computed tomography (mCT), decalcified in EDTA/PBS (pH 7.5)
for 2 weeks, paraffin-embedded, and processed for histology. All
procedures on animal experiments were approved by the local
ethical committee for Animal Research (Katholieke Universiteit
Leuven). The animals were housed according to the guidelines of
the Animalium Leuven (Katholieke Universiteit Leuven).
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Bone quantification
To quantify ectopic bone formation, we used mCT to quantify
the volume of new bone formed in three dimensions by
segmenting the newly formed mineralized tissues from the
calcium phosphate grains in each material. For segmentation, a
manually selected, but consistent global threshold value was
used for each scaffold. The choice of threshold value was
confirmed by visual comparison to the corresponding histologi-
cal sections.
Histological analysis
We performed histological staining on paraffin-embedded
sections of cell/biomaterial constructs. Hematoxylin and eosin
(H&E) and TRAP staining was carried out as previously
described,(8) and TRAP-positive osteoclasts were visualized using
fluorescent microscopy, and quantified using ImageJ software.
For CD31 immunohistochemistry, the tissue sections underwent
antigen retrieval in proteinase K for 15 minutes at 958C and were
blocked in 1% normal rabbit serum, before being incubated
overnight at 48C with rat anti-mouse CD31 (BD Pharmingen;
1:20). Sections were then probed with the biotinylated
rabbit anti-rat IgG antibody (Vector Laboratories, Peterborough,
UK; 1:100), and the signal was amplified with the Vector
Laboratories ‘‘ABC system.’’ The signal was detected using 3,30-
diaminobenzidine (DAB), the sections were counterstained with
hematoxylin, and the number of CD31-positive vessels per
scaffold was visually quantified.
Statistical analysis
The data were processed using the Statistical software package
StatView 5.0.1 (SAS Institute, Inc., Cary, NC, USA). Normally
distributed data were analyzed using one-way ANOVA tests with
a post hoc Fisher’s least significant difference test for multiple
comparisons. The nonparametric Kruskal-Wallis and Mann-
Whitney U test were used when data appeared to be not
normally distributed. No other corrections for multiple compar-
isons were made. Values of p less than or equal to 0.05 were
considered statistically significant. Statistical significance is
indicated on all graphs as follows: p< 0.05; p< 0.01; and
p< 0.001.
Results
Circulating early osteoclast precursors are increased in
critically ill patients
To establish whether cells from critically ill patients are triggered
to differentiate into osteoclasts before any in vitro manipulation,
the number of osteoclast precursors present in critically ill
patient or healthy control peripheral blood was assessed by
FACS analysis. Double-positive CD14þ/CD11bþ cells are consid-
ered to be early osteoclast precursors, and triple-positive CD14þ/
CD11bþ/VNRþ cells are considered to be mature circulating
osteoclasts.(4,16) The population of viable mononuclear cells were
first gated for 7-AAD (viability dye) and CD14 (Fig. 1A). From this
population, the cells that were also CD11b-positive were then
gated, and classed as ‘‘early osteoclast’’ precursors. There were
significantly more early osteoclast precursors (CD14þCD11bþ) in
the blood of critically ill patients than in blood from healthy
controls (99.1% versus 83.9%, respectively; p< 0.05; Fig. 1A, B).
From this population of viable, CD14/CD11b-positive cells, ‘‘late
osteoclast’’ precursors that were also positive for vitronectin
receptor (VNR) were then determined; however, no significant
increase in mature circulating osteoclasts was observed
(CD14þCD11bþVNRþ) (Fig. 1A, C).
Osteoclast formation is increased in critically ill patient
PBMC cultures in vitro
To further examine the cause of bone loss during critical illness in
a clinically relevant model, PBMCs were isolated and pooled from
an age-, sex-, and BMI-matched set of critically ill patients and
healthy controls, and analyzed for osteoclast formation and
activity. To assess whether these precursor cells form active
osteoclasts, the isolated PBMCs were cultured for 14 days in FBS,
with and without RANKL andM-CSF, and the number and activity
of osteoclasts in patient cultures were compared with healthy
matched controls. After 14 days of culture with RANKL and M-
CSF, the formation of mature, multinuclear (3 nuclei, TRAP-
positive) osteoclasts was 17-fold higher in PBMC cultures from
critically ill patients than those from healthy controls (Fig. 2A (I), B;
p< 0.05). Analysis of osteoclast activity was carried out by
quantifying the degree of hydroxyapatite resorption after
culturing the cells for 21 days in hydroxyapatite-coated wells.(12)
This revealed a 36-fold higher resorption in patient PBMC
cultures with RANKL and M-CSF as compared with controls
(Fig. 2A (II), C; p< 0.05). Importantly, PBMCs from critically ill
patients also differentiated into osteoclasts without RANKL and
M-CSF (24-fold increase versus healthy cells); however, these
osteoclasts were unable to resorb hydroxyapatite, suggesting
that the presence of humoral osteoclastogenic factors is
necessary for the formation of active osteoclasts (Fig. 2A (II), C).
Autologous critically ill patient serum increases osteoclast
formation and activity
To assess the impact of humoral factors in the patient’s blood on
the differentiation potential of PBMCs into osteoclasts, PBMCs
from patients and healthy controls were cultured in the presence
of 10% autologous patient serum (PS) or 10% autologous healthy
serum (HS). Culturing patient PBMCs in 10% PS resulted in a
4-fold increase in osteoclast formation compared to patient
PBMCs grown with 10% HS, both with and without RANKL and
M-CSF (Fig. 3A, B; p< 0.05). Importantly, osteoclasts formed from
patient PBMCs in PS without RANKL and M-CSF also displayed
increased F-actin ring formation (6-fold), and actively resorbed
hydroxyapatite (2-fold increase) compared to patient cultures
grown in 10% HS (Fig. 3A, C, D; p< 0.05). These data suggest the
presence of humoral factors present in patient serum that
promote mature, active osteoclast formation and activity.
Interestingly, the addition of 10% PS to cultures of healthy
control PBMCs did not increase osteoclast formation or
resorption, in the presence or absence of RANKL and M-CSF
(Fig. 3A–C). These data suggest a unique interaction between
patient cells and PS that is not present in healthy control cultures
and PS.
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Inhibition of the immunomodulatory receptor FcgRIII in
patient serum decreases in vitro osteoclast formation in
patient PBMCs
In order to assess whether the humoral factors that seem to
interact with the primed PBMCs from critically ill patients could
be attributed to the elevated levels of themajor proinflammatory
cytokines or other immunomodulatory factors, cells were grown
in 10% PS with neutralizing antibodies for inflammatory
cytokines IL-6 and TNF-a, and/or the immunoreceptor FcgRIII.
Interestingly, blocking IL-6 or TNF-a activity did not reduce the
formation of TRAP- and F-actin ring–positive, actively resorbing
osteoclasts (Fig. 4A–C). However, upon the addition of anti-
FcgRIII, osteoclast formation and activity was significantly
reduced compared to control cultures (69.2%; p< 0.05), or
compared to PBMCs grownwith cytokine neutralizing antibodies
(61.4%; p< 0.05) (Fig. 4A–D).
Critically ill patient serum does not affect osteoblast
differentiation but reduces expression of angiogenesis
markers in vitro
In order to assess the impact of circulating factors during critical
illness on bone formation, an in vitro model of osteogenesis
during critical illness was established. For this purpose, we used
hPDCs, a population of mesenchymal cells isolated from the
human periosteum, that have shown to proliferate, migrate, and
differentiate into chondrogenic and osteogenic lineages upon
stimuli such as trauma, fracture, or infection.(13,17) Cells were
cultured for 21 days in osteogenic medium, as previously
described.(13,18) As a late marker of hPDC osteoblast differentia-
tion, calcium deposition was measured quantitatively using
Alizarin Red staining on differentiated hPDCs.
Addition of FBS, HS, or PS to the osteogenic medium did not
affect differentiation or mineralization of the cells (Fig. 5A, B).
Also, gene expression analysis of osteogenic markers RUNX2
and COL1A1 (type I collagen) revealed no difference between PS
and HS (despite a reduction in expression of these genes in both
these groups as compared with cells grown in FBS) (Fig. 5C, D).
Expression of ALP (bone-specific alkaline phosphatase) was also
not different between PS and HS (Fig. 5E). These data suggest
that osteogenic differentiation is unaffected by circulating
factors during critical illness assessed in vitro. Interestingly,
expression of the angiogenesis factor VEGF alpha (VEGFA) was
not different between PS and HS groups (Fig. 5F), although a
reduction in VEGF-receptor 1 (VEGFR1) expression with PS as
compared with HS was detected at the gene and protein
level, suggesting that angiogenesis may be compromised
during bone formation and skeletal healing in critical illness
(Fig. 5G, H).
In an in vivo murine model, bone formation is reduced
with patient serum, coinciding with increased osteoclast
activity and reduced angiogenesis
Bone formation is a multifactorial process involving a tightly
regulated cascade of events, which include the recruitment,
proliferation, and differentiation of osteoprogenitor cells, along
with the formation of a well-defined vascular compartment.
Therefore, although no differences in osteogenesis in the
presence of PS were observed with hPDCs in vitro, it was
plausible that aberrant bone formation might still occur in vivo,
possibly through deficient angiogenesis. In order to test this
hypothesis, hPDCs were incubated with FBS, HS, or PS for 7 days
in basal medium, before being seeded onto calcium phosphate
Fig. 1. Circulating osteoclast precursors in healthy and critically ill patient peripheral blood. (A) Representative dot plots of the gating of viable CD14þ
PBMCs, CD14þ/CD11bþ early osteoclast precursors and CD14þ/CD11bþ/VNRþ mature osteoclasts in healthy and patient peripheral blood samples
matched for age, sex, and BMI. (B) FACS analysis revealed a significant increase in early osteoclast precursors (CD14þ/CD11bþ) from the peripheral blood of
critically ill patients (99.8% 0.38% and 83.9% 7.09%, respectively) (n¼ 5; p< 0.01). (C) A trend toward an increase in mature circulating osteoclasts
(CD14þ/CD11bþ/VNRþ) was also observed (n¼ 5; p¼ 0.09).
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(CaP) NuOss scaffolds overnight, transplanted into NMRI-nu/nu
mice, and incubated for 8 weeks.(8) Upon explantation and
analysis of bone formation by mCT, scaffolds containing PS-
treated hPDCs revealed significantly less mature bone than those
containing HS-treated cells (28.9% reduction) (Fig. 6A). No
significant differences in calcium phosphate granules or fibrous
tissue compartments were observed. In view of the increased
osteoclast activity observed in previous experiments, possibly
contributing to bone hyperresorption in critical illness, the trend
for an increase in osteoclastic activity in PS scaffolds, as detected
by TRAP staining, was unsurprising (Fig. 6B). The local vasculature
is vital for the formation of new bone during normal bone
maintenance and following fracture. Upon explant, PS scaffolds
contained visibly less vascularization than HS scaffolds. There-
fore, the formation of blood vessels was measured with CD31
immunohistochemistry, which revealed that vascularization was
significantly reduced in PS scaffolds (Fig. 6C).
Discussion
In the current study we have attempted to identify the cellular
and humoral factors regulating bone resorption and formation
during critical illness. The cellular effects of human critical illness
were studied in vitro, where PBMC osteoclast precursors in the
blood of critically ill patients seemed to possess a long-lasting
‘‘memory’’ of the critical illness, resulting in increased osteoclast
formation compared to healthy controls. This was further
potentiated by humoral factors present in the serum from
critically ill patients. Unexpectedly, neutralizing the inflammatory
cytokines TNF-a and IL-6 in patient serum did not inhibit
osteoclast formation in patient PBMC cultures; however,
blocking signaling through the immunoreceptor FcRgIII inhib-
ited osteoclast formation both in the presence and absence of
cytokine neutralizing antibodies, suggesting immunomodulato-
ry mechanisms may be involved. In an in vitro model of bone
Fig. 2. Human in vitro study of osteoclast differentiation. (A) Formation of mature, multinuclear osteoclasts was visualized by TRAP positivity (scale
bar¼ 100mm) (I) and resorption on hydroxyapatite (scale bar¼ 500mm) (II) in healthy or patient cultures with FBS, in the presence and absence of RANKL
and M-CSF. (B) The number of TRAP-positive multinuclear cells was significantly increased in critically ill patient PBMC cultures with and without RANKL
and M-CSF. (C) Resorption of hydroxyapatite was increased in patient cultures in the presence and absence of RANKL and M-CSF (n¼ 8; p< 0.05 versus
healthy cells).
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Fig. 3. Effect of critically ill patient serum on osteoclast differentiation and activity. (A) Formation of mature, multinuclear osteoclasts was visualized
by TRAP positivity (top row), F-actin ring formation (second row), formation of multinuclear cells (third row, merged image of TRAP, DAPI, and F-actin
ring staining) (scale bar¼ 100mm), and resorption on hydroxyapatite (bottom row; analyzed with Von Kossa staining; scale bar¼ 500mm) in pooled
PBMC cultures from healthy controls and critically ill patients. (B) The number of TRAP-positive multinuclear cells was significantly increased in
patient PBMC cultures without (white bars) andwith (gray bars) osteoclastogenic factors RANKL andM-CSF, in the presence of PS. (C) F-actin ring formation
was also significantly increased in the presence of patient serum in patient PBMC cultures in the absence (white bars) and presence (gray bars) of
RANKL and MCSF. (D) Resorption of hydroxyapatite was increased in patient cultures cultured with 10% HS or 10% PS in the absence (white bars)
and presence (gray bars) of RANKL and MCSF (n¼ 8; p< 0.05 versus patient cells plus HS and healthy cells plus PS; ap< 0.05 versus healthy cells
plus HS).
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formation, we were unable to reveal an effect of critical illness on
osteoblast differentiation that could explain the reduction of
bone formation observed in vivo, although a reduction in VEGF-
R1 gene and protein expression in vitro, together with a
reduction in vascularization in vivo suggests that reduced
angiogenesis may play a role.
During critical illness, markers of bone resorption are highly
elevated by up to 4-fold, whereas markers of bone formation are
reduced.(2) In addition, survivors of critical illness experience an
increased risk in fragility fractures up to 8 years following ICU
discharge.(3) Although critically ill patients are immobilized for
long periods of time, in a recent study analyzing bone turnover
markers in 40 patients immobilized by stroke for a minimum of
6 months, the bone resorption marker Serum CrossLaps was
increased by 2-fold,(19) suggesting that the extreme bone
hyperresorption observed during critical illness cannot be
explained by immobilization alone.
In our study, FACS analysis carried out on fresh human
peripheral blood samples from critically ill patients revealed a
significant increase in circulating early osteoclast precursors,
suggesting that, even prior to in vitro manipulation, critically ill
patient PBMCs display increased osteoclastogenic potential. This
increase in osteoclast precursors is often characterized by an
increase in osteoclast formation and activity, which can be
recapitulated in vitro through the isolation and differentiation of
PBMCs into osteoclasts, with the addition of osteoclastogenic
factors such as RANKL and M-CSF. In the current study, PBMCs
were isolated from healthy controls and critically ill patients and
pooled, in order to reduce genetic variability and study the effect
critical illness on osteoclast formation, rather than individual
patient conditions. Pooled PBMCs from critically ill patients
displayed a significant increase in differentiation into osteoclasts
compared to healthy controls, both in the presence and absence
of RANKL and M-CSF. However, these mature, multinuclear
osteoclasts were only able to actively resorb hydroxyapatite in
the presence of humoral factors. Numerous other studies have
reported that, in vitro, PBMCs isolated from patients of Paget’s
disease, osteoporosis, phenylketonuria, multiple myeloma, and
Fig. 4. Inhibition of the immunomodulatory receptor FcgRIII in patient serum decreases in vitro osteoclast formation. (A) Formation of mature,
multinuclear osteoclasts was visualized by TRAP (left panel; scale bar¼ 100mm), F-actin ring formation (middle panel; scale bar¼ 100mm), and resorption
(right panel; scale bar¼ 100mm) in pooled PBMC cultures from critically ill patients with 10% PS and anti-IL-6/TNF-a (1mg/mL and 8mg/mL, respectively),
anti-FcgRIII (20mg/mL), or a combination of anti-IL-6/TNF-a and anti-FcgRIII. The number of TRAP-positive multinuclear cells (B), F-actin rings per well
(C), and the percentage area resorbed (D) was significantly reduced in patient PBMC cultures with anti-FcgRIII, or a combination of anti-FcgRIII and
anti-IL-6/TNF-a, compared to control cultures, or cultures with anti-IL-6/TNF-a alone (n¼ 4; p< 0.001 versus control cultures, ap< 0.001 versus
anti-IL-6/TNF-a).
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rheumatoid arthritis display spontaneous differentiation into
mature osteoclasts.(4,9,16,20) Interestingly, during in vitro osteo-
clast differentiation of PBMCs from chronic liver disease patients
with osteopenia,(21) ‘‘spontaneously’’ formed osteoclasts re-
quired the exogenous addition of M-CSF and RANKL to resorb
bone, suggesting that these factors are essential for osteoclast
activity.
In the current study, osteoclast formation and activity was
further increased in patient PBMC cultures upon the addition of
10% PS, whereas no increase was observed with HS, or in healthy
PBMC cultures treated with PS. This suggested that crosstalk
between factors within the PS and patient PBMCs may have
promoted osteoclastogenesis. Inflammatory cytokines have
previously been shown to promote the formation of osteoclasts
in vitro and in vivo,(22–24) and have been directly related to
fragility fractures in postmenopausal females.(22) However,
surprisingly, neutralizing antibodies for both TNF-a and IL-6
did not suppress osteoclast formation in patient PBMC cultures
with 10% PS, suggesting that other factors present in the serum
such as RANKL may have been involved. RANKL and
osteoprotegerin (OPG) have both been previously measured
in patients with critical illness.(2) Although levels of RANKL were
undetectable, levels of OPG were significantly increased 3-fold in
critically ill patients compared to healthy controls upon intensive
care admission, and decreased significantly throughout the
time in intensive care (while levels of serum b–cross-linked
C-telopeptide [CTX] and urinary deoxypyridinoline [DPD]
increased). High serum concentrations of the decoy receptor
OPG and low serum concentrations of RANKL have been
reported in disorders resulting in secondary osteoporosis, such
as primary biliary cirrhosis.(25) In addition, a number of studies
have reported increased levels of serum OPG in multiple
myeloma (MM) patients compared to healthy controls, which
decreases over time.(7) Recently, the importance of immuno-
modulatory factors in diseases of bone metabolism has become
apparent.
Fig. 5. Effect of critically ill patient serum on osteogenic differentiation and angiogenesis in vitro. (A) Alizarin Red staining of hPDCmonolayers cultured for
21 days in 10% FBS, 10% HS (‘‘Healthy’’) or 10% PS (‘‘Patient’’). (B) Alizarin Red staining quantified by assessment of optical density at 540 nm revealed no
significant difference in mineralization between Healthy and Patient serum treatment. qRT-PCR analysis of (C) RUNX2, (D) COL1A1, (E) ALP, and (F) VEGFA
normalized to b-actin revealed no differences in gene expression between HS and PS conditions, although a reduction in VEGF-R1 expression was
observed in patient serum conditions (G), which was also observed at the protein level (H). (n¼ 8; p< 0.001 versus FBS; p< 0.01 versus FBS; ap< 0.01
versus healthy serum).
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In immune complex–mediated reactions, the amplitude of
inflammatory responses is believed to depend on the ratio of
activating and inhibitory Fcg receptors (FcgR). Three classes of
FcgR are expressed in monocytes: FcgRI, FcgRII, and FcgRIII.
FcgRIII (also known as CD16) is an activating receptor whose
expression is increased in inflammatory bone disorders such as
psoriatic arthritis, rheumatoid arthritis, and osteoporosis.(7,20) In
the current study, blocking FcgRIII/CD16 expression in patient
PBMC cultures caused a significant decrease in osteoclast
formation, which was sustained when inflammatory cytokines
IL-6 and TNF-a were also blocked. This suggests that humoral
factors and/or IgG antibodies in critically ill patient serummay be
acting through the FcgRIII/CD16 receptor to increase osteoclast
formation in patient PBMC cultures.
In addition to an increased risk of fractures during rehabilita-
tion, such bone hyperresorption could also predispose
critically ill patients to impaired healing of traumatic and
surgical bone lesions. For instance, prolonged critical illness
may compromise sternal healing following sternotomy for
cardiac surgery, resulting in poor outcome.(26) In order to
investigate the effect of critical illness on bone formation during
skeletal repair, critically ill patient serum was applied to the
cells presently considered essential for fracture healing, namely
hPDCs.(8,17,27)
Fig. 6. Effect of critically ill patient serum on bone formation in vivo. (A) Bone quantification of hPDC NuOSS implants was carried out using mCT analysis
8 weeks after implantation in nude mice, and revealed a significant reduction in bone formation in patient-serum conditions compared to healthy serum
(mature bone¼ yellow; remaining CaP grains¼ blue). No significant differences in CaP grains or fibrous tissue were detected in the scaffold. (black
bars¼ FBS; gray bars¼healthy serum; white bars¼patient serum). (B) A trend toward an increase in the number of TRAP-positive osteoclasts per scaffold
in patient serum-treated hPDCs was observed, although this did not reach significance (p¼ 0.07; scale bar¼ 200mm). (C) Upon explant, scaffolds coated
with patient serum-treated hPDCs had visibly less vasculature than scaffolds coated with healthy serum hPDCs (insets). This was confirmed by
quantification of CD31 immunohistochemistry, with a significant reduction in the number of CD31-positive blood vessels in scaffolds with patient serum
treated hPDCs (scale bar¼ 50mm) (n¼ 4; p< 0.001 versus healthy serum; ap< 0.01 versus FBS).
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In order to heal the fracture, multipotent periosteal cells must
differentiate into osteoblasts to mediate bone formation.
Previous studies have reported that human serum isolated
from juvenile idiopathic arthritis patients has a negative effect on
osteoblast differentiation in vitro, possibly due to the high levels
of cytokines present in the serum.(28) Therefore, the impact of
prolonged critically ill patient serum on the differentiation
capacity of hPDCs was evaluated by mineralization of the
extracellular matrix with calcium deposition. Although an
increase in mineralization was observed in all differentiated
conditions compared to nondifferentiated cells, no differences
were observed between HS or PS. Similarly, gene expression of
RUNX2, COL1A1, and ALP revealed no differences in expression
between HS and PS conditions, although a reduction in RUNX2
and COL1A1 expression was observed in both human serums
compared to the standard FBS condition. Although these
findings suggest that in vitro, factors such as inflammatory
cytokines present in critically ill PS do not have an effect on
osteogenic differentiation, the fact that the expression of VEGF-
R1 at both the gene and protein level was significantly reduced
with PS suggests that vascularization may be inhibited during
skeletal healing and bone formation in critical illness.
This hypothesis was corroborated by the in vivomodel of bone
formation during critical illness, where a reduction in bone
formation in PS-coated NuOss scaffolds implanted in NMRI-nu/
numice correlated with a significant reduction in vascularization,
along with an increase in osteoclast activity. This finding directly
supports the hypothesis that hypoxia is a major risk factor for
impaired fracture healing, such as evidenced by sternal healing
problems after internal mammary artery harvesting for coronary
bypass surgery.
The present study has, for the first time, investigated the
difficult problem of extreme bone loss during critical illness at
the cellular and tissue level. Increased circulating osteoclast
precursors in critically ill patients seemed to maintain their
osteoclastogenic phenotype when studied in vitro, and were
stimulated further by factors such as IgG antibodies present in
critically ill patient serum, which enhanced the ‘‘primed’’
osteoclast activity. Additionally, although osteogenesis did not
seem to be affected by critical illness in vitro, bone formation in
calcium phosphate scaffolds was hampered in vivo, possibly due
to reduced angiogenesis brought about by circulating factors.
The identity of these factors remains to be investigated.
Our data may help to define novel therapeutic targets to
prevent bone loss and optimize fracture healing in critically ill
patients.
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